News

Dr. Reddy’s ANDA is approved by the United States Food & Drug Administration (USFDA). The Allegra-D 12 Hour brand has U.S. sales of approximately $49.8 million for the

As part of the acquisition agreement, Apellis obtained the necessary intellectual property rights to develop its complement inhibitor drug compound (APL-2) in ophthalmology and plans its first clinical

The Notice of Allowance is for U.S. Patent Application No. 14/230,053, "Compositions for Treatment of Attention Deficit Hyperactivity Disorder" owned by Highland’s wholly owned subsidiary, Ironshore Pharmaceuticals &

The grant, with additional funding from Heptares, will support a three-year research project aimed at developing first-in-class, selective and orally available small molecule GLP-1 receptor antagonists for the

The inability to detect this overpouch mislabeling at the point of care may result in the administration of a dose lower than intended. In thehigh-risk patient population –

Maternal immunization is a strategy to protect newborns through the transfer of maternal antibodies via active transport mechanisms in the placenta, thus providing the infant the benefit of

The new 120,000m² facility will provide increased capacity for compounds within the company’s immunology and oncology pipelines. The Singapore site includes a contained API facility, additional buildings and

Hysingla ER is a once-daily, single-entity medication formulated using the company’s extended-release solid oral platform, RESISTEC, which uses a combination of polymer and processing that confers tablet hardness

Dupilumab is indicated for AD patients who are not adequately controlled with topical prescription therapy and/or for whom these treatments are not appropriate. It is an investigational therapy